Bristol-Myers Squibb-Bristol-Myers Q1 Earnings Review: A Decidedly Mixed Bag - Rating Downgrade

If you like what you have just read and want to receive at least 4 exclusive stock tips every week focused on Pharma, Biotech and Healthcare, then join me at my marketplace channel, Haggerston BioHealth . Invest alongside the model portfolio or simply access the investment bank-grade financial models and research. I hope to see you there.Revenues came to $11.2bn, down 6% year-on-year on a constant currency basis. Non-GAAP earnings per share ("EPS") came to$ 1.80, and GAAP EPS $1.20, compared to$ (4.40) and ...